The medical diagnostics company Deepull, a member of CATALONIA.HEALTH, has announced the closing of a €50 million Series C financing round. The round was co-led by Columbus Venture Partners, Panakès Partners, and Mérieux Equity Partners. Also, it had the participation from existing investors as Asabys Partners, Aliath Bioventures, both also members of CATALONIA.HEALTH, and other investors as Innvierte-CDTI, We Venture Capital, UI Investissement, Axis-ICO, and Kurma Partners.
Proceeds from the Series C will be deployed to finalize clinical validation and expedite the regulatory approval process of deepull’s UllCORE diagnostic system, which received Breakthrough Device Designation from the U.S. Food and Drug Administration in December 2024. UllCORE is a fully automated, walkaway system, which uses cutting edge molecular techniques to extract and detect microbial DNA directly from whole blood.
Jordi Carrera, CEO of deepull, said: “This financing marks a critical step forward for deepull as we move towards completing the clinical studies of our diagnostic system. With this support, we are poised to deliver a transformative diagnostic solution to healthcare providers and patients worldwide.”
Rick Ivey, Chairman of the Board of Directors at deepull, commented: “The strong support and oversubscription in this financing round reflect both the strength of deepull’s technology and its potential to redefine diagnostic standards”.
Comments